HealthPersonalized mRNA melanoma vaccine cuts recurrence risk in late-stage trial
Trial data show a 42% lower combined chance of melanoma returning or patients dying among recipients of Moderna and Merck’s tailored mRNA shot than with usual care.
N
NBC News★★★☆☆2026-10-23 18:42Original
Personalized mRNA melanoma vaccine cuts recurrence risk in late-stage trial
Health